Premium
Human platelet response to three salicylate dosage forms
Author(s) -
Thiessen J. J.,
Grad H.,
Macleod S. M.,
Spino M.
Publication year - 1983
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510040107
Subject(s) - sodium salicylate , chemistry , platelet , in vivo , serotonin , pharmacology , platelet rich plasma , high performance liquid chromatography , chromatography , plasma levels , salicylic acid , endocrinology , medicine , biochemistry , biology , receptor , microbiology and biotechnology
Acetylsalicylic acid (ASA) inhibition of platelet aggregation as evaluated by collagen‐induced 14 C‐serotonin release, has been measured in 12 healthy male subjects. Each subject received a single oral dose (650 mg) of enteric‐coated ASA (ecASA) and compressed ASA tablets (cASA), or ecASA and sodium salicylate (578 mg) separated by a minimum of 5 weeks. The platelet response was related to plasma ASA and salicyclic acid determined by high‐pressure liquid chromatography. Both ecASA and cASA inhibited 14 C‐serotonin release; no significant difference was observed in the maximum effect between these two products ( p > 0·05). No relationship was found between the maximum observed plasma ASA level and the maximum effect. Further, no correlation was found between the maximum inhibition of 14 C‐serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations.